gptkbp:instanceOf
|
gptkb:drug
|
gptkbp:approvalYear
|
1976
|
gptkbp:ATCCode
|
gptkb:C07AB03
|
gptkbp:bioavailability
|
50% (oral)
|
gptkbp:CASNumber
|
gptkb:29122-68-7
|
gptkbp:contraindication
|
asthma
heart block
severe bradycardia
cardiogenic shock
|
gptkbp:drugClass
|
beta blocker
|
gptkbp:eliminationHalfLife
|
6-7 hours
|
gptkbp:excretion
|
gptkb:kidney
|
gptkbp:hasChEMBLId
|
gptkb:CHEMBL402
|
gptkbp:hasInChIKey
|
METKIMKYRPQLGS-UHFFFAOYSA-N
|
gptkbp:hasMolecularFormula
|
C14H22N2O3
|
gptkbp:hasSMILES
|
CC(C)NCC(CO)OC1=CC=C(C=C1)CC(=O)N
|
gptkbp:hasUNII
|
50VV3VW0TI
|
gptkbp:hasWikipediaPage
|
https://en.wikipedia.org/wiki/Atenolol
|
https://www.w3.org/2000/01/rdf-schema#label
|
CHEMBL402
|
gptkbp:indication
|
gptkb:arrhythmia
myocardial infarction
hypertension
angina pectoris
|
gptkbp:isApprovedDrug
|
true
|
gptkbp:legalStatus
|
prescription only
|
gptkbp:manufacturer
|
gptkb:AstraZeneca
|
gptkbp:mechanismOfAction
|
beta-1 adrenergic receptor antagonist
|
gptkbp:MeSH_ID
|
D000889
|
gptkbp:metabolism
|
minimal hepatic
|
gptkbp:molecularWeight
|
266.34
|
gptkbp:name
|
gptkb:Atenolol
|
gptkbp:pregnancyCategory
|
C (US)
|
gptkbp:proteinBinding
|
6-16%
|
gptkbp:PubChem_CID
|
gptkb:D00222
2162
CHEBI:2269
DB00335
|
gptkbp:routeOfAdministration
|
oral
|
gptkbp:sideEffect
|
dizziness
fatigue
bradycardia
cold extremities
|
gptkbp:synonym
|
gptkb:Atenololum
gptkb:Tenormin
4-(2-Hydroxy-3-isopropylaminopropoxy)phenylacetamide
|
gptkbp:target
|
gptkb:ADRB1
gptkb:ADRB2
|
gptkbp:bfsParent
|
gptkb:ketamine
gptkb:MDMA
|
gptkbp:bfsLayer
|
6
|